Search Results 1771-1780 of 19558 for Hemoglobin

  1. A Study to Evaluate Binimetinib in Combination with Encorafenib in Patients with Pancreatic Malignancies and a Somatic BRAFV600E Mutation - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (obtained ≤ 14 days prior to registration). Total bilirubin ≤ 1.5 x upper limit of normal (ULN) (obtained ≤ 14 days prior to ...

  2. A Study of Response, Survival, Safety, and Tolerability of Lenvatinib for the Treatment of Anaplastic Thyroid Cancer - Mayo Clinic

    Hemoglobin ≥ 9.0 g/dL (can be corrected by growth factor or transfusion); Platelet count ≥ 100 x 10^9/L. Adequate blood coagulation function as evidenced by ...

  3. A Study of Biomarker-Directed, Pembrolizumab (MK-3475) Based Combination Therapy for Advanced Non-Small Cell Lung Cancer (MK-3475-495) - Mayo Clinic

    Hemoglobin ≥.0 g/dL or ≥.6 mmol/L*. Renal. Creatinine OR Measured or calculated** creatinine clearance (GFR can also be used in place of creatinine or CrCl); ...

  4. Isatuximab in Treating Patients With Relapsed or Refractory Primary Amyloidosis - Mayo Clinic

    Patients must have hemoglobin ≥ 8 g/dL within 28 days prior to registration. Patients may have received transfusion if greater than 7 days prior to ...

  5. Neurosciences Clinical Trials - Medical Professionals

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  6. Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC - Mayo Clinic

    Hemoglobin: ≥9.0 g/dL 6. Serum creatinine ≤1.5 × ULN 10. Patients must be able to practice required contraception during the study. 1. For males ...

  7. Baricitinib In Relapsing Giant Cell Arteritis - Mayo Clinic

    Hemoglobin < 10 grams/deciliter; Total white blood cell count (WBC) < 2500 cells/μL); Neutropenia (absolute neutrophil count [ANC] < 1200 cells/μL; Lymphopenia ...

  8. Tafasitamab, Lenalidomide and Venetoclax for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma - Mayo Clinic

    * Hemoglobin \> 8.0 g/dL (obtained =\< 14 days prior to registration) * Activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) ...

  9. Neurosurgery - Clinical trials

    In addition to belonging to one of these 16 subcohorts, patients will be required to have bloodwork demonstrating a blood hemoglobin ≥ 10 g/dL, a ...

  10. A Study to Evaluate the Effectiveness and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma - Mayo Clinic

    Hemoglobin | ≤ 9.0 g/dL (transfusion allowed with 2-week washout period);; ANC | ≤ 1.5 × 109/L. Hepatic. ALT | > 2.5 × ULN (> 5 × ULN if related to ...